Processing...
Clinical Trials for Melanoma
Search
Search
There are 161 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
161 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic or unresectable BRAF V600–mutant melanoma who are stable on or have progressed after prior BRAF/MEK therapy receive standard dabrafenib/trametinib or encorafenib/binimetinib with added nilotinib. Nilotinib (a BCR-ABL/c-KIT/PDGFR tyrosine kinase inhibitor) is dose-escalated to assess safety, pharmacokinetics, and preliminary activity of this triplet strategy; treated, stable brain metastases allowed.
ClinicalTrials.gov ID: NCT04903119
TrialFetch AI summary: Adults with unresectable stage III–IV melanoma (ECOG 0–2), including PD-1–naïve metastatic patients or those with stable/partial response on ongoing PD-1 after ≥12 weeks and prior adjuvant checkpoint or BRAF/MEK allowed; excludes active diabetes requiring meds, active CNS disease, significant immunosuppression, or autoimmune disease needing systemic therapy. Patients receive pembrolizumab alone or pembrolizumab plus metformin (AMPK activator/mitochondrial complex I inhibitor aimed at reversing T-cell metabolic insufficiency) to assess immunometabolic and clinical benefit.
ClinicalTrials.gov ID: NCT03311308
TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) after standard therapy failure; phase 1 tests oral GIM‑531 monotherapy (including NSCLC, TNBC, platinum‑resistant ovarian, and AKT3‑altered tumors), and phase 2 treats melanoma, NSCLC, or RCC that progressed on anti‑PD‑1 with continued anti‑PD‑1 plus GIM‑531. GIM‑531 is a first‑in‑class, Treg‑selective small‑molecule inhibitor linked to AKT3/PI3K–AKT pathway modulation to suppress Tregs and potentially restore antitumor immunity.
ClinicalTrials.gov ID: NCT06425926
TrialFetch AI summary: Adults with metastatic cutaneous melanoma, including those refractory to prior PD-1/PD-L1 therapy and with at least one resectable lesion for TIL harvest, receive non-myeloablative lymphodepletion followed by autologous TIL infusion and high-dose IL-2, with most eligible patients also receiving pembrolizumab (anti–PD-1) given peri- and post-infusion. Patients with controlled small asymptomatic brain metastases may enroll; key exclusions include significant autoimmune disease, active infections, major cardiopulmonary compromise, and prior severe immune-related toxicities to PD-1/PD-L1 agents for the pembrolizumab arm.
ClinicalTrials.gov ID: NCT02621021
TrialFetch AI summary: Adults with unresectable stage III–IV cutaneous melanoma (non-uveal), treatment-naïve for metastatic disease, receive ipilimumab plus fixed-dose nivolumab/relatlimab with added sarilumab, an interleukin‑6 receptor–blocking antibody intended to mitigate immune-related toxicity and potentially enhance efficacy. Excludes active/untreated brain metastases, active autoimmune disease requiring systemic therapy, and significant immunosuppression.
ClinicalTrials.gov ID: NCT05428007
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Enrolls adults with relapsed/refractory or treatment-ineligible advanced/metastatic solid tumors (ECOG 0–1) who have at least two injectable lesions, with emphasis on cutaneous and head/neck cancers (e.g., cSCC, BCC, melanoma, Merkel cell carcinoma, HNSCC) including anti–PD-1–refractory cohorts. Patients receive intratumoral MQ710/MQ719, a non-replicating modified vaccinia Ankara virotherapy (E5R-deleted to enhance cGAS/STING signaling and engineered to express Flt3L and OX40L), given in escalating multi-dose schedules alone or combined with systemic pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT05859074
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–2), including heavily pretreated patients (HLA-A*02:01–positive patients generally expected to have received prior tebentafusp when available), are treated with NBM-BMX, an oral HDAC8-selective histone deacetylase inhibitor aimed at epigenetic modulation to promote tumor cell-cycle arrest and apoptosis. NBM-BMX is given as empty-stomach oral capsules twice daily in continuous 28-day cycles with dose escalation (100–400 mg BID) followed by expansion until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042